Pre-clinical research
Pre-clinical Trials
Phase 1 trial
Phase 2 trial
Phase 3 trial
FDA Approved
Generally Available
Phase 3 trial
Live-attenuated
1112
The vaccine is made from a harmless virus that’s been altered to produce the surface spike protein from SARS-CoV-2.
Early analysis of trial data showed the vaccine stopped an average of 70% of participants from falling ill, but effectiveness rose to 90% for one of two dosing regimes, using half a dose followed by a full one later. Among those who received the vaccine, there were no severe cases, and no participants were hospitalized.